These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32384884)

  • 21. Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA.
    Tu KY; Wu MK; Chen YW; Lin PY; Wang HY; Wu CK; Tseng PT
    Medicine (Baltimore); 2016 Jan; 95(4):e2411. PubMed ID: 26825882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder.
    Kotzalidis GD; Lombardozzi G; Matrone M; Amici E; Perrini F; Cuomo I; De Filippis S
    Curr Neuropharmacol; 2021; 19(12):2296-2307. PubMed ID: 33441069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
    Jacobson W; Zhong W; Nomikos GG; Christensen MC; Kurre Olsen C; Harvey PD
    Curr Med Res Opin; 2020 Jan; 36(1):117-124. PubMed ID: 31422713
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC; Florea I; Lindsten A; Baldwin DS
    J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA).
    Yang YK; Chen CS; Tsai CF; Chang CM; Lai TJ; Lee CT; Lin CC; Lan TH; Herr KJ
    Curr Med Res Opin; 2021 Dec; 37(12):2163-2173. PubMed ID: 34515596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
    McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
    BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Safety of Vortioxetine in the Chinese Population.
    Miao J; Wang G; Hou J; Areberg J; Zhao Y; Højer AM; Ettrup A
    Adv Ther; 2019 Nov; 36(11):3134-3146. PubMed ID: 31552551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between insulin resistance and serum insulin-like growth factor 1 levels in patients with non-remitting major depressive disorder.
    Arinami H; Suzuki Y; Watanabe Y; Tajiri M; Tsuneyama N; Someya T
    J Affect Disord; 2024 Jan; 344():612-616. PubMed ID: 37802324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
    Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
    J Neurochem; 2024 Sep; 168(9):1817-1825. PubMed ID: 37635396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.
    Bose R; Hamdani SU; Minhas FA; Herr KJ
    Curr Med Res Opin; 2022 May; 38(5):661-671. PubMed ID: 35049384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.
    Sharma AN; da Costa e Silva BF; Soares JC; Carvalho AF; Quevedo J
    J Affect Disord; 2016 Jun; 197():9-20. PubMed ID: 26956384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study.
    Zhang Y; Lai S; Zhang J; Wang Y; Zhao H; He J; Huang D; Chen G; Qi Z; Chen P; Yan S; Huang X; Lu X; Zhong S; Jia Y
    J Affect Disord; 2024 Apr; 351():799-807. PubMed ID: 38311073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
    CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
    Murthy NV; Xu R; Zhong W; Harvey PD
    J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
    McIntyre RS; Harrison J; Loft H; Jacobson W; Olsen CK
    Int J Neuropsychopharmacol; 2016 Jun; 19(10):. PubMed ID: 27312740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
    Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
    Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine.
    Lachaine J; Beauchemin C; Bibeau J; Patenaude J; Chokka P; Proulx J; Bougie J
    CNS Spectr; 2020 Jun; 25(3):372-379. PubMed ID: 31120009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.